ABSTRACT
After the identification of the new Coronavirus disease (COVID-19) in December 2019, it has spread rapidly around the world. The COVID-19 pandemic has forced medical systems to limit their services, promote teiehealth, prolong visits to clinics, and postpone scheduled surgical operations. The mortality rate of COVID-19 in patients with lung cancer appears to be significantly higher than that of patients with other cancers. Medical care offered to patients with lung cancer should take into account the risk of COVID-19 associated with visits to clinics and treatments. This review outlines the efforts of lung cancer oncologists in the 'With COVID-19" era based on the current evidence and statements from domestic and foreign academic societies and organizations. © 2021 Japanese Journal of Cancer and Chemotherapy Publishers Inc.. All rights reserved.